Clinical Trials Logo

Fatty Liver clinical trials

View clinical trials related to Fatty Liver.

Filter by:

NCT ID: NCT02880189 Completed - Obesity Clinical Trials

EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity

Start date: December 2016
Phase: N/A
Study type: Interventional

This study is designed to investigate the impact of weight loss achieved with the IGB on NASH with early fibrosis in a select cohort of patients with obesity preselected to have a high pre-test probability of having NASH with early fibrosis based on magnetic resonance elastography (MRE)-Hepatogram. In addition, this study will explore potential non-invasive imaging criteria for NASH and early fibrosis using EUS-Elastography.

NCT ID: NCT02875821 Completed - Clinical trials for Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)

Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone

Start date: April 26, 2016
Phase: Phase 4
Study type: Interventional

In this study, the investigators investigate beneficial effects of ipragliflozin, newly developted SGLT2 inhibitor, on reduction in visceral fat area and degree of fatty liver in subjects with T2DM when added to metformin and pioglitazone therapy.

NCT ID: NCT02875392 Completed - Clinical trials for Non-alcoholic Fatty Liver Disease

Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

Start date: November 2016
Phase: N/A
Study type: Interventional

Studies reveal special function of fucoidan so far include anti-virus, anti-tumor, immunomodulatory, anti-inflammatory, blood fat, anti-oxidation and liver and kidney dysfunction and improve fibrosis. The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

NCT ID: NCT02873507 Withdrawn - Fatty Liver Clinical Trials

Prediction of Donor Liver Adipose Content by Magnetic Resonance Imaging

Start date: May 2018
Phase: N/A
Study type: Interventional

A pilot prospective cohort study assessing the clinical utility of MRI evaluation of graft steatosis prior to transplantation will be conducted. An MRI of the donor liver within the transport cooler will be obtained on its way to the operating room.

NCT ID: NCT02863757 Recruiting - Chronic Hepatitis B Clinical Trials

Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease

Start date: August 2016
Phase:
Study type: Observational

The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).

NCT ID: NCT02863393 Withdrawn - Clinical trials for Non-alcoholic Fatty Liver Disease

Diaphragmatic Breathing Exercise Improves Non-alcoholic Fatty Liver Disease

Start date: August 29, 2017
Phase: N/A
Study type: Interventional

The non-alcoholic fatty liver disease is increasing and associated with obesity, diabetes and hyperlipidemia in recent years. Aerobic exercise indeed reduces adipose, hepatic insulin resistance and hepatic fat. However, diaphragmatic breathing improves cardiopulmonary function, the oxygen content of the body and therefore reduces inflammation of cells. The aim of this study is to ameliorate hepatic inflammation by using diaphragmatic breathing exercises instead of aerobic exercise to reduce the fat in liver inflammation.

NCT ID: NCT02860884 Completed - Clinical trials for Non-alcoholic Fatty Liver Disease

Using Infrared Spectroscopy for Diagnosis Severity of Nonalcoholic Fatty Liver Disease

NASH
Start date: August 2014
Phase: N/A
Study type: Observational

The main objective of this study is to evaluate the ability of infrared spectroscopy to discriminate simple hepatic steatosis from NASH

NCT ID: NCT02856555 Completed - Clinical trials for Nonalcoholic Steatohepatitis (NASH)

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

Start date: August 8, 2016
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of firsocostat in adults with nonalcoholic steatohepatitis (NASH).

NCT ID: NCT02855164 Terminated - Clinical trials for Non-alcoholic Steatohepatitis (NASH)

Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

FLIGHT-FXR
Start date: August 1, 2016
Phase: Phase 2
Study type: Interventional

The purpose of the study was to assess the effects of different doses of tropifexor (LJN452) with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

NCT ID: NCT02854605 Completed - Clinical trials for Nonalcoholic Steatohepatitis (NASH)

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Start date: October 26, 2016
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).